Published Paper Details:

Modern implant therapy offers significant functional and biologic advantages for many patients when compared to conventional fixed or removable prostheses, and it also produces excellent long-term results, as evidenced by numerous 10-year studies with success and survival rates above 95%. As a result, it is a treatment modality that is frequently used in daily practice for fully and partially edentulous patients. Biomimetic agents, also known as biometric agents, are substances that may be implanted and copy or imitate certain bodily functions or structures (physiology). The specifications for implantable biometric agents Ability to promote the development of the proper cells to improve new bone production, reduced danger of infectious contagious disease transfer by simple synthesis or manufacture that avoids extraction from allografts, avoiding issues with implant loss owing to coating delamination by resorbability in response to osteogenic activity, chemical stability prior to implant insertion, no immune reaction generation. A bone-creating implant being tested in clinical settings by Nobel Biocare. The bone morphogenic protein rhBMP-2 (a recombinant form of a naturally occurring human protein) will be used to treat this implant, and the researchers assert that this treatment will fundamentally alter the indications for dental implants. Bovine bone filler demonstrated a low substitution rate and is widely used, not only for contour augmentation in early implant placement but also for internal augmentation. Bone fillers not only mechanically support barrier membranes to reduce risk of membrane collapse during healing, but they also have biologic properties, such as osteogenic potential to activate new bone formation, and a high or a low substitution rate, which will influence the stability of augmented bone. Implants are the latest trend to improve aesthetics and longevity of prosthesis.